Although SGLT2 inhibitors may have some unfavorable side effects, the overall performance of this class of drugs appears to be quite promising for many patients suffering from CKD, reduced Glomerular Kidney Filtration (GFR), and albuminuria. This evidence concerns the gene SLC5A2 and chronic kidney disease.